These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 8994321

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP, Cho CJ, Elkins WR, Wyatt LS, Moss B, Murphy BR.
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [Abstract] [Full Text] [Related]

  • 4. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R, Brownlie R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [Abstract] [Full Text] [Related]

  • 5. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T, Davoodi F, Cho CJ, Skiadopoulos MH, Durbin AP, Collins PL, Murphy BR.
    Vaccine; 2000 Jan 31; 18(14):1359-66. PubMed ID: 10618533
    [Abstract] [Full Text] [Related]

  • 6. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC, McAuliffe JM, Murphy BR, Collins PL.
    J Virol; 2001 May 31; 75(10):4594-603. PubMed ID: 11312329
    [Abstract] [Full Text] [Related]

  • 7. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
    Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL.
    J Virol; 1987 Nov 31; 61(11):3416-23. PubMed ID: 2822951
    [Abstract] [Full Text] [Related]

  • 8. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
    Garg R, Brownlie R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Vaccine; 2017 Dec 18; 35(51):7139-7146. PubMed ID: 29153777
    [Abstract] [Full Text] [Related]

  • 9. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T, Skiadopoulos MH, Davoodi F, Riggs JM, Collins PL, Murphy BR.
    J Virol; 2000 Jul 18; 74(14):6448-58. PubMed ID: 10864657
    [Abstract] [Full Text] [Related]

  • 10. Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.
    Tang RS, Schickli JH, MacPhail M, Fernandes F, Bicha L, Spaete J, Fouchier RA, Osterhaus AD, Spaete R, Haller AA.
    J Virol; 2003 Oct 18; 77(20):10819-28. PubMed ID: 14512532
    [Abstract] [Full Text] [Related]

  • 11. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, Wertz GW.
    J Virol; 1987 Dec 18; 61(12):3855-61. PubMed ID: 3316707
    [Abstract] [Full Text] [Related]

  • 12. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
    Mason JN, Elbahesh H, Russell CJ.
    J Virol; 2013 May 18; 87(10):5959-69. PubMed ID: 23514887
    [Abstract] [Full Text] [Related]

  • 13. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B.
    Vaccine; 1999 Oct 14; 18(5-6):392-7. PubMed ID: 10519927
    [Abstract] [Full Text] [Related]

  • 14. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R, Latimer L, Gomis S, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Antiviral Res; 2019 Feb 14; 162():54-60. PubMed ID: 30550799
    [Abstract] [Full Text] [Related]

  • 15. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
    Spriggs MK, Collins PL, Tierney E, London WT, Murphy BR.
    J Virol; 1988 Apr 14; 62(4):1293-6. PubMed ID: 2831389
    [Abstract] [Full Text] [Related]

  • 16. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T, Skiadopoulos MH, Durbin AP, Davoodi F, Collins PL, Murphy BR.
    Vaccine; 1999 Mar 05; 17(9-10):1100-8. PubMed ID: 10195620
    [Abstract] [Full Text] [Related]

  • 17. Parainfluenza virus type 3 (PIV3)-specific and non-virus-specific delayed type hypersensitivity responses in cotton rats given different PIV3 antigen preparations.
    Ambrose MW, Wyde PR.
    Vaccine; 1993 Mar 05; 11(3):336-42. PubMed ID: 8383384
    [Abstract] [Full Text] [Related]

  • 18. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
    Durbin AP, Skiadopoulos MH, McAuliffe JM, Riggs JM, Surman SR, Collins PL, Murphy BR.
    J Virol; 2000 Aug 05; 74(15):6821-31. PubMed ID: 10888621
    [Abstract] [Full Text] [Related]

  • 19. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S, Saul S, Dai J, Surman S, Liu X, Park HS, Le Nouën C, Lingemann M, Dahal B, Coleman JR, Mueller S, Collins PL, Buchholz UJ, Munir S.
    Proc Natl Acad Sci U S A; 2024 Jun 18; 121(25):e2316376121. PubMed ID: 38861603
    [Abstract] [Full Text] [Related]

  • 20. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
    Skiadopoulos MH, Tao T, Surman SR, Collins PL, Murphy BR.
    Vaccine; 1999 Oct 14; 18(5-6):503-10. PubMed ID: 10519940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.